tbuckley/cabot-search huggingface dataset:
Poetry’s Company
Authors: Jed Myers
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Imaging and molecular biomarkers: a novel approach to screen populations at risk of pulmonary fibrosis?
Authors: Ivan O. Rosas
Journal: European Respiratory Journal (2016)

An estimated 90 million subjects in the USA have a history of smoking, and are therefore at risk of developing smoke-related lung diseases including lung cancer, chronic obstructive pulmonary disease (COPD) and pulmonary fibrosis. An ageing population, the lack of effective diagnostic and therapeutic approaches, and the modest impact of smoking cessation strategies largely explain why chronic lower respiratory diseases are presently a leading cause of death in the US adult population [1]. In 2014, a US National Heart, Lung and Blood Institute task force concluded that effective primary and secondary prevention of chronic lung diseases will require focused efforts to determine risk factors and characterise early-stage disease in at-risk groups. Additionally, development of surrogate measures such as imaging and molecular biomarkers are required to support the design of randomised clinical trials to test chronic lung disease preventive strategies [2]. LDCT lung cancer screening in smokers may detect subclinical COPD and pulmonary fibrosis <http://ow.ly/zfOq304aWy5>
TCT-515 Prognostic implications of instantaneous wave-free ratio (iFR) and resting distal-to-aortic pressure ratio (Pd/Pa) compared with fractional flow reserve (FFR). A 10-year follow-up study after deferral of revascularization
Authors: Tim van de Hoef, Gilbert Wijntjens, Martijn Meuwissen, Mauro Echavarria Pinto, Martijn van Lavieren, Karel Koch, Steven Chamuleau, Michiel Voskuil, Robert de Winter, Jan Tijssen, Jan Piek
Journal: Journal of the American College of Cardiology (2016)
Chemoradiotherapy in multicentric glioblastoma multiforme—A clinical study
Authors: S. Papaiah Susheela, A. Bahl, P. R, D. Sharma, P. Julka, G. Rath
Journal: Journal of Clinical Oncology (2006)

11525 Background: Glioblastoma multiforme constitutes 40% of primary brain tumors. Multicentric Glioblastoma multiforme is rare about 3%.No definite guidelines is available in literature for management of these tumors. Methods: All Multicentric Glioblastoma multiforme were analyzed retrospectively from Jan 2003 to July 2005 for clinical behavior and response to chemoradiotharpy. Either Temozolamide or Carboplatin or Paclitaxel is used concurrently with radiation. Radiation dose 60 Gy/30 fractions over 6 weeks by bilateral parallel opposed fields was delivered using Cobalt-60 machine. Results: 27 cases were found, Male: Female 24:3, KPS 60 [40–70], Majority of them are symptomatic for 4 months, main symptoms were seizures, headache, vomiting, neurological deficite. 89% of them underwent one form of other surgical intervention. 11% were diagnosed on basis of radiological findings. 85% were supratentorial, 15% were both supra and infratentorial, one of which had spinal cord lesion. 6 [22%] patients did not receive any treatment. Among 21 patients 4 were treated only with radiotherapy, 17 with concurrent Chemoradiotherapy [Paclitaxel-8, Temozolamide-7 and Carboplatin-2]. 5 patients did not complete treatment. Among 16 patients only 6 came for first follow up, 5 of were concurrent Chemoradiotherapy [Temozolamide-4, Paclitaxel-l and RT alone 1]. At the end of 3 months only 2 patients with Temozolamide were alive. Conclusions: Multicentric Glioblastoma multiforme is an aggressive disease. Concurrent Chemoradiotherapy with Temozolamide has better role. No significant financial relationships to disclose.
General practices achieve 95% of QOF points
Authors: Gareth Iacobucci
Journal: BMJ (2016)

General practices in England achieved 95% of their available Quality and Outcomes Framework (QOF) points last year, official figures have shown.1

The figures from NHS Digital showed that practices achieved an average score of 532.9 QOF points out of 559 in 2015-16. This represented a slight increase from the average of 529.6 points out of 559 in 2014-15.2

The highest levels of achievement from practices last year were for …
Haplo-Identical Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome: Similar Survival in Comparison with HLA-Identical Siblings: Multi-Center, Prospective Study
Authors: Yu Wang, Wu Depei, Qifa Liu, Lin Liu, Feng Gao, Jian ou-Yang, Dai-Hong Liu, Lan-Ping Xu, Xiao-Jun Huang
Journal: Blood (2014)
CHR-2845, a Monocyte/Macrophage Targeted Histone Deacetylase Inhibitor In a First In Man Clinical Trial In Subjects with Advanced Haematological Malignancies
Authors: Gert Ossenkoppele, Bob Lowenberg, Pierre Zachee, Norbert Vey, Dimitri Breems, Arjan A. Van de Loosdrecht, Phillip Debnam, Lindsey Needham, Lindsay Bawden, Leon Hooftman
Journal: Blood (2010)
P0573 : A strategy to favor the access of irregular and refugee migrants to a screening program for HBV, HCV AND HIV infection
Authors: N. Coppola, L. Alessio, L. Gualdieri, M. Pisaturo, C. Sagnelli, N. Caprio, R. Maffei, M. Starace, I.F. Angelillo, G. Pasquale, E. Sagnelli
Journal: Journal of Hepatology (2015)
CRITERIOS DE MAL PRONÓSTICO DE LOS PÓLIPOS MALIGNOS (PT1)
Authors: M Alburquerque Miranda, L Vidal Plana, A Smarrelli, C Ledezma Frontado, A Vargas García, M Figa Franscesch, F Gonzalez-Huix Llado
Journal: Endoscopy (2016)

Introducción: Los criterios de mal pronóstico (CxP) en los pólipos malignos (PT1) predicen la infiltración ganglionar y guían la indicación de cirugía radical.
Bone Marrow Transplantation For Thalassemia Using Related Other Than HLA- Identical Siblings: Improved Transplant Outcomes With a Novel Approach
Authors: Javid Gaziev, Marco Marziali, Antonella Isgro, Pietro Sodani, Katia Paciaroni, Cristiano Gallucci, Gioia De Angelis, Cecilia Alfieri, Marco Andreani, Manuela Testi, Michela Ribersani, Luisa Cardarelli, Daniele Armiento, Guido Lucarelli
Journal: Blood (2013)
TCT-697 Comparison of Outcomes of Transcatheter Aortic Valve Replacement plus Percutaneous Coronary Intervention versus Transcatheter Aortic Valve Replacement Alone in the United States
Authors: Vikas Singh, Badal Thakkar, Alexis Rodriguez, Nileshkumar Patel, Apurva Badheka, Carlos Alfonso, Mauricio Cohen, Igor Palacios, Ignacio Inglessis, Sammy Elmariah, William O'Neill
Journal: Journal of the American College of Cardiology (2016)
TCT-47 Secular Trends in Characteristics, Treatments, and Outcomes in Patients with Unprotected Left Main Coronary Artery Disease Over Two Decades
Authors: Duk-Woo Park, Se Hun Kang, Seung-Jung Park, Pil Hyung Lee, Jung-Min Ahn, Mineok Chang, Sung-Han Yoon, Soo-Jin Kang, Seung-Whan Lee, Young-Hak Kim, Cheol Whan Lee, Seong-Wook Park
Journal: Journal of the American College of Cardiology (2016)
TCT-232 The Glasgow MRI Rotational Atherectomy Study (GlaMoRoS): HSRA PCI is associated with a low rate of peri-procedural MI and a significant improvement in ischemic burden
Authors: David Corcoran, Colin Berry, Guillaume Clerfond, David Carrick, Kenneth Mangion, Barry Hennigan, John Paul Rocchiccioli, Aleksandra Radjenovic, Mitchell Lindsay, Hany Eteiba, Keith Oldroyd, Margaret McEntegart
Journal: Journal of the American College of Cardiology (2016)
TCT-268 Impact of diabetes on outcomes after percutaneous coronary intervention in patients according to race/ethnicity
Authors: Birgit Vogel, Usman Baber, Jaya Chandrasekhar, Melissa Aquino, Samantha Sartori, Serdar Farhan, Michela Faggioni, Gennaro Giustino, Pooja Vijay, Srushti Shah, Jason Kovacic, Pedro Moreno, Prakash Krishnan, George Dangas, Roxana Mehran, Annapoorna Kini, Samin Sharma
Journal: Journal of the American College of Cardiology (2016)
TCT-537 What can intracoronary pressure measurements tell us about flow reserve? Pressure-bounded CFR and its application to the randomized DEFER trial
Authors: Frederik Zimmermann, Nico Pijls, Bernard De Bruyne, Jan-Willem Bech, Pepijn van Schaardenburgh, K. Lance Gould, Nils Johnson, Richard L. Kirkeeide
Journal: Journal of the American College of Cardiology (2016)
STUDIES ON IMMUNOLOGICAL RELATIONSHIPS AMONG THE PNEUMOCOCCI
Authors: John Y. Sugg, Emidio L. Gaspari, William L. Fleming, James M. Neill
Journal: The Journal of Experimental Medicine (1928)

The paper reports a study of a virulent, S-producing strain of Pneumococcus which is immunologically related to, but not identical with typical strains of Type III pneumococcus. In a potent anti-Type III serum, the relationship of this strain to typical Type III strains appears to be about the same as the relationship of Avery's Subgroup Type II strains to typical Type II. But a more pronounced distinction is evident in the antiserum produced by immunization with the strain related to Type III. This antiserum contained antobodies specifically reactive with typical Type III bacteria as well as antibodies reactive with the homologous strain, while anti-Subgroup Type II immune sera are devoid of antibodies reactive with typical Type II pneumococci. The result of absorption experiments were the same as those usually obtained with immunologically related, but not identical bacteria. The failure of reciprocal absorption and the marked variations in the relative potencies of the antiserum from different individual animals might be presented as presumptive evidence that two different anti-S antibodies are contained in Type III immune horse serum. The theoretical significance of virulent pneumococci which are related to but not identical with the "fixed" types, is discussed from the standpoint of their importance in the biological classification of the Pneumococcus group.
Polyplex micelle installing intracellular self-processing functionalities without free catiomers for safe and efficient systemic gene therapy through tumor vasculature targeting
Authors: Qixian Chen, Kensuke Osada, Zhishen Ge, Satoshi Uchida, Theofilus A. Tockary, Anjaneyulu Dirisala, Akitsugu Matsui, Kazuko Toh, Kaori M. Takeda, Xueying Liu, Takahiro Nomoto, Tekihiko Ishii, Makoto Oba, Yu Matsumoto, Kazunori Kataoka
Journal: Biomaterials (2016)
Tricyclic antidepressant medication use and non-Hodgkin lymphoma: A Danish population-based cohort study
Authors: S. O. Dalton, A. H. Poulsen, M. Noergaard, J. K. McLaughlin, C. Johansen, S. Friis
Journal: Journal of Clinical Oncology (2008)

8578 Background: An increased risk of non-Hodgkin lymphoma (NHL) has been reported among long-term users of tricyclic antidepressants. Methods: We calculated the incidence of NHL among all 43,932 users (≥2 prescriptions) of antidepressant medication in the county of North Jutland, Denmark, during 1989–2003 and compared with NHL incidence in the population of North Jutland not using antidepressant medication (<2 prescriptions) using Poisson regression analysis adjusted for age, gender, period, use of immunosuppressive drugs, corticosteroids or NSAIDs. Results: Use of tricyclic antidepressants was associated with an overall increased incidence of NHL (adjusted incidence rate ratio (IRR): 1.53; 95% confidence interval (CI): 1.06–2.21) compared with non-use. The IRR in users with ≥10 prescriptions and five or more years of follow-up was 2.50 (95% CI: 1.43–4.34). In users of SSRI the overall IRR of NHL was 1.25 (95% CI, 0.88, 1.79) but when excluding the first year of follow-up there was no excess incidence and no trend was observed with either number of prescriptions or length of follow-up. Conclusions: Our results indicate an increased risk of NHL among long-term users of tricyclic antidepressant medications. Antidepressant use is prevalent and this finding warrants additional studies with sufficient power to investigate risk by type and dosage of antidepressant medication as well as by lymphoma subgroups. No significant financial relationships to disclose.
Prognostic factors in relapsed or refractory male germ cell tumors: Results from an international study of 1,593 patients
Authors: A. Lorch, J. Beyer, C. Mollevi, M. Guerra, A. Kramar
Journal: Journal of Clinical Oncology (2009)

5030 Background: The results of salvage treatment in male patients (pts) with relapsed or refractory germ-cell tumors (rr-GCT) depend considerably on prognostic factors. However, individual factors are not broadly accepted. Methods: Between 09/2007 and 12/2008 data on 1984 pts with rr-GCT were collected from 38 centers/groups worldwide. Inclusion criteria were (1) First line treatment for metastatic GCT after January 1, 1990; (2) Cisplatin and etoposide as part of first-line regimens; (3) No first-line high-dose chemotherapy (HDCT); (4) Relapse or progression after first-line treatment; (5) Cisplatin- based conventional-dose regimens or HDCT as salvage treatment. Data were centrally reviewed and checked for consistency. The primary endpoint was progression-free survival (PFS). Prognostic factors were identified using Cox multivariate regression analysis. Results: Overall 1593 (80%) pts fulfilled the strict inclusion criteria. Salvage treatment given as consolidation of first-line treatment in patients without progression was the most frequent cause of exclusion. Median follow-up was 58 months (range 1 to 206 months). Three-year PFS for the entire group was 38% (95% CI: 35%-40%), the overall survival was 51% (95% CI: 48%-54%). Multivariate analysis on a randomly selected 2/3 training dataset identified the following variables as the most significant ones for PFS: see Table . Cisplatin-refractory or absolute refractory disease was a confounding factor for response to first-line treatment. Conclusions: This preliminary analysis of a large dataset allowed the identification of important prognostic factors in rr- GCT. A prognostic score for first-salvage treatment based on the results of a final analysis will be presented. [Table: see text] No significant financial relationships to disclose.
Response Rates Using International Working Group (IWG) Criteria in Patients with Myelodysplastic Syndromes (MDS) Treated with Azacitidine.
Authors: Lewis R. Silverman, David R. McKenzie, Bercedis L. Peterson, Carlos M. De Castro, John Ellerton, Kathryn N. Knapp, C.L. Beach, Richard A. Larson
Journal: Blood (2005)
TCT-524 Invasive minimal Microvascular Resistance (mMR); a new index to assess microcirculatory dysfunction that is not modulated by the presence of angiographic coronary artery disease
Authors: Guus de Waard, Sukhjinder Nijjer, Martijn van Lavieren, Nina van der Hoeven, Ricardo Petraco, Tim van de Hoef, Mauro Echavarria Pinto, Sayan Sen, Peter van de Ven, Paul Knaapen, Javier Escaned, Jan Piek, Justin Davies, Niels van Royen
Journal: Journal of the American College of Cardiology (2016)
AML At First Relapse: A Real Life Picture
Authors: Eileen Mary Boyle, Claude Preudhomme, Olivier Nibourel, Catherine Roche-Lestienne, Gareth J Morgan, Brigitte Dupriez, Isabelle Plantier, Berengere Gruson, Jean Pierre Marolleau, Delphine Lebon, Jose Fernandes, Christophe Willekens, Bruno Quesnel, Céline Berthon
Journal: Blood (2013)
Antimicrobial prophylaxis during high dose cytarabine consolidation in acute myeloid leukemia.
Authors: Randall Ingham, Michael Cardin, John Leonard Reagan
Journal: Journal of Clinical Oncology (2015)

e17644 Background: Given the paucity of data and concern over fostering antibiotic resistance we examined the practice of prophylactic antimicrobial use in AML patients during high dose cytarabine (HiDAC) consolidation. Methods: All patients who received HiDAC consolidation between 1/2007-7/2014 were reviewed. HiDAC was defined as a dose ≥1g/m2. Medical records were reviewed to determine patient characteristics (Table). Patients were divided into those who received antimicrobials and those who did not. The primary endpoint was incidence of neutropenic fever leading to hospitalization with secondary endpoints of incidence of bacteremia, resistant bacteria, invasive fungal infection, C. dif infection, and death from infection. Chi square and Wilcoxon rank sum tests were used for analysis. Results: 183 patient events (64 no antimicrobials, 119 antimicrobial prophylaxis) met inclusion criteria. The prophylaxis group was older, had a higher Charlson Comorbidity Index, and received a lower dose of cytarabine. No significant difference in the incidence of bacteremia, invasive fungal infection, or C. dif infection was seen. A significantly higher incidence of infection with resistant bacteria (MRSA and methicillin resistant coagulase negative staph) was seen in the prophylaxis group (Table). Conclusions: Antimicrobial prophylaxis during HiDAC did not reduce the number of neutropenic fever episodes. Further, there was no impact on rates of bacterial, fungal, or C. dif infection. Higher rates of infection with resistant bacteria were seen in the prophylaxis group. During HiDAC, the role of antimicrobial prophylaxis is questionable and may be detrimental due to increased rates of resistant organism infections. Prospective studies are required to further validate this finding. AML HiDAC patient characteristics. Yes Antimicrobial prophylaxis N=119 No Antimicrobial prophylaxis N=64 P value Age (mean) 51.3 46.4 0.05 Charlson Comorbidity Index (mean) 2.7 2.2 0.05 Cytarabine dose (g/m2, mean) 2.27 2.44 0.05 Hospitalized for neutropenic fever 75 33 0.11 Bacteremia 27 9 0.44 Resistant bacterial infection 16 1 0.008 Invasive fungal infection 2 1 0.89 C. dif infection 5 4 0.47 Death from infection 1 1 0.65
TCT-674 Sex Specific Outcomes of TAVR with the Sapien 3 Valve: Insights From The PARTNER 2 S3 High-Risk and Intermediate-Risk Cohorts
Authors: Molly Szerlip, Sarah Gualano, John Squiers, Jonathon White, Darshan Doshi, Isaac George, Nicolas Vazquez, John Michael Dimaio, Raj Makkar, Mathew Williams, Howard Herrmann, Lars Svensson, John Webb, Rebecca Hahn, Ajay Kirtane, Vasilis Babaliaros, Vinod Thourani, Maria Alu, Susheel Kodali, Martin Leon, Michael Mack
Journal: Journal of the American College of Cardiology (2016)
Thyroid lymphoma: A single institution’s experience
Authors: E. M. Wallace, D. G. Power, G. D. Leonard, D. N. Carney
Journal: Journal of Clinical Oncology (2007)

18533 Background: Extranodal lymphomas account for a significant proportion of non-Hodgkin’s lymphomas. Thyroid lymphoma accounts for &lt;2% of these. Lymphoma represents approximately 2% of all malignant thyroid tumours and is almost always of B-cell lineage. The main presenting symptom is a rapidly enlarging goiter and approximately half present with disease limited to the thyroid gland, designated stage IE. Due to its rarity, there is limited information with regard to prognosis or management. Pre-existing chronic autoimmune (Hashimoto’s) thyroiditis is the only known risk factor. Methods: We retrospectively reviewed all cases of thyroid lymphoma found in our institution over a 15 year period (1985–2000). Eleven patients were identified as suitable for analysis. Diagnosis and staging involved a full history and physical examination with relevant serology. Radiological imaging included computerized tomography, plain radiographs and ultrasound. Bone marrow aspirate and biopsy were performed in ten of the patients and patients were then staged according to the Ann Arbour Classification. We specifically analysed patients for their epidemiological features, presentation, treatment and their overall outcome. We compared our data to those from earlier series. Results: Seven of the 11 patients were female with a median age of diagnosis of 56. Most patients complained of neck swelling for a number of months but dysphagia, dyspnoea and hoarseness (80%) were the symptoms that prompted presentation. Hashimoto’s thyroiditis was not found. The commonest histological subtype was diffuse large B cell lymphoma (45% of cases). Seven patients had stage I disease, 3 stage II and 1 stage IV. Nine patients received chemotherapy and radiotherapy was administered in the adjuvant setting to nearly half of the patients. No correlation between presentation and other diagnostic tests or survival was found. Two-year survival for our patients was 100% and no cases died from their disease. Conclusion: Thyroid lymphoma is a rare disease and valuable information on this subject has been provided by single institution studies. Our encouraging survival figures are likely a combination of the predominance of early stage disease and the use of combined modality therapy. The use of monoclonal antibodies may provide a further benefit to these patients. No significant financial relationships to disclose.
IWG-MRT 2013 Criteria-Based Assessment of Response Among 83 Patients with Myelofibrosis Treated with JAK Inhibitors: Experience of Two Centers
Authors: Lisa Pieri, Emanuela Sant'Antonio, Elisa Rumi, Paola Guglielmelli, Rajmonda Fjerza, Chiara Paoli, Lucia Merli, Mario Cazzola, Alessandro M. Vannucchi
Journal: Blood (2015)